Quantum Computing, Inc. (NASDAQ: QUBT) — A $1.4 Billion Bond Fund in a Quantum Costume

Independent Equity Research Report date: 2026-07-11 Price (2026-07-10): ~$8.66 · Shares out: ~226M (10-Q cover) / ~238M (data-feed) · Market cap: ~$1.95–2.06B Cash + investments (3/31/26): ~$1.41B · Total debt: ~$3.7M (leases) · Implied EV: ~$0.55–0.65B FY2025 revenue: $682K · FY2025 operating loss: −$51.1M · Sector: Information Technology · Quantum Computing / Photonics Hardware

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The analysis that follows is deliberately position-free and carries no price target; this block is the single exception.

Verdict: AVOID as an investment; NOT a clean short. Effectively “no position” — a $1.4B securities portfolio wearing a quantum-computing costume, trading at a ~25–40% premium to the cash inside it. Conviction: medium.

Strip away the narrative and QUBT is a closed-end bond fund. At 3/31/26 it held ~$1.41B of cash and short-dated, investment-grade debt securities ($565M U.S. Treasuries + $570M corporate bonds + odds and ends), against ~$3.7M of lease debt and a business that produced $682K of revenue in all of 2025 while losing $51M at the operating line. The cash throws off more interest income (~$54M annualized) than the operating business loses in most quarters, which is genuinely unusual and gives the stock a hard-ish floor at roughly cash-per-share ~$6.2 / book ~$7.1. At $8.66 you are paying ~$0.55–0.65B of enterprise value — everything above the cash — for (a) a photonic “entropy quantum computer” that no peer-reviewed benchmark has validated and whose gate-based version has not been prototyped, and (b) a just-bolted-on, ~83%-goodwill photonics-components roll-up (Luminar Semiconductor, bought out of a bankruptcy estate) assembled to manufacture a revenue line. That is a very expensive lottery ticket layered on top of a T-bill account.

Two things stop me from calling it an outright short, and they matter. First, the cash floor is real and liquid — this is not a going concern, and a value-oriented buyer below cash would have a genuine arbitrage. Second, the tape is a retail-momentum machine (beta ~2.5, “Space & Quantum” factor loading of ~4.2, −95% max drawdown but +90%/yr over three years) that can squeeze violently on any quantum headline — a Google milestone, the pending Quantinuum IPO, another Trump executive order. What tips me firmly negative on owning it here is the human evidence: insiders sold ~$33.8M and bought exactly zero into the 2025 spike — the founder/CEO/Chairman personally cashed ~$22M and gifted away 2.4M more shares — while the company itself top-ticked a $1.25B raise at ~$18–20 within days of the all-time high. Management has, in effect, already told you what this stock is worth by selling it to you. Layer on three CEOs in two years, a combined CEO/Chairman, options that vest fully on grant with no performance hurdles, a prior auditor (BF Borgers) the SEC shut down for sham audits, a 2024 restatement, still-open material weaknesses, and an active securities-fraud class action plus four derivative suits — and the quality bar is on the floor.

Framing: cash-shell-plus-a-lottery-ticket, priced at a premium to the cash. The rational long is not “buy the quantum future” — it is “buy the cash box near or below its cash value and get the option for free.” At $8.66 you are not getting it for free. Where I’d get constructive: at/below net cash (~$6.2–7.0), as a cash-box-with-optionality, I’d move to HOLD. What flips me bullish: an independently benchmarked quantum-advantage result or a credible, multi-year commercial foundry revenue ramp (not $120K/quarter) that justifies the operating EV on its own. What flips me more bearish: insider selling resuming, another dilutive raise despite the $1.4B hoard, an LSI goodwill impairment, or an adverse turn in the fraud litigation. Tag: “The narrative is the product; the cash is the collateral.”

📈 Stock Price Action — Five-Year Event Map

QUBT round-tripped from a sub-$1 penny stock to a ~$21 quantum-mania darling and roughly halfway back. Over the trailing five years the adjusted close ran from a low of ~$0.36 (Jul 2024) to a high of ~$21.00 (Oct 7, 2025), and sits at ~$8.66 today — about 59% below the peak, with a 52-week range of roughly $6.18–$20+. The stock is a high-beta (~2.5), lottery-shaped instrument: three-year annualized return ~+90% but a max drawdown of −95.6%. The moves below are facts; the attributed drivers are interpretation.

Cycle narrative. (1) The stock spent 2021–2024 bleeding out as a diluting micro-cap. (2) Google’s Willow announcement in December 2024 detonated a retail quantum mania and QUBT, as one of the few pure-play tickers, went up ~15× in eight weeks. (3) Nvidia CEO Jensen Huang’s January 8, 2025 comment that useful quantum computing was “15–20 years” away collapsed the cohort. (4) The group recovered through 2025, and — critically — management used the strength to raise $1.25B in September–October private placements at ~$18–20, within days of the all-time high. (5) As the mania cooled and ~4× dilution was absorbed, the stock ground back to ~$6.50 by March 2026. (6) The Luminar Semiconductor and NuCrypt acquisitions (Feb–Mar 2026) and a wave of favorable Washington headlines (the June 2026 Trump quantum executive orders) drove a ~78% bounce. (7) The most recent leg is a quiet fade back to ~$8.66. Each figure ties to five-year daily price history and is cross-referenced to earnings prints, 8-K events, and public news.

1. Executive Summary

Quantum Computing, Inc. (“QCi” / QUBT) is a Hoboken, NJ–based company that markets a portfolio of photonics-based products under a quantum banner: the “Dirac” Entropy Quantum Computer (EQC), the “Neurawave” photonic reservoir computer, single-photon LiDAR/vibrometry, quantum random-number and quantum-authentication prototypes, and a thin-film lithium niobate (TFLN) photonic-chip prototyping foundry (“Fab 1”) in Tempe, Arizona. It is one of a handful of listed pure-play quantum names (alongside IonQ, D-Wave, and Rigetti) that trade as a correlated, retail-driven, story-stock basket.

The central fact of the investment case is the balance sheet, not the technology. QUBT sold 86.25 million shares for $1,475 million across four private placements in 2025 — 81% of it in September–October at ~$18–20, days from the all-time high — and parked the proceeds in a portfolio of U.S. Treasuries and investment-grade corporate bonds. At March 31, 2026 the company held ~$1.41 billion of cash and marketable securities, roughly 87% of total assets, against essentially no debt. That hoard generates ~$54 million of annualized interest income, which exceeds the operating loss in most quarters and gives the stock an unusually firm floor around cash-per-share (~$6.2) and book (~$7.1).

The operating business, by contrast, is negligible and unproven. FY2025 revenue was $682 thousand at a 10% gross margin; the operating loss was −$51.1 million and widening. Q1 2026 revenue of $3.7 million looks like a step-change but ~$3.5 million of it came entirely from two acquisitions that closed mid-quarter — Luminar Semiconductor (LSI), bought for $110 million cash (~83% booked as goodwill) out of Luminar Technologies’ bankruptcy estate, and NuCrypt LLC. Organic (legacy quantum) revenue was ~$204 thousand, at a negative gross margin. The core quantum computer has no peer-reviewed quantum-advantage validation; the gate-based version has not been prototyped (a key engineering metric sits at ~2 million versus a required ~10 million); and management itself concedes broad quantum advantage “may take years or decades … if it ever” arrives.

Capital allocation is bifurcated. Raising ~$1.5 billion by selling story stock at the top of a mania was genuinely shrewd corporate finance — the single value-accretive act in the file. But the proceeds sit in T-bills with no deployment plan proportional to their size, the acquisitions are ~83%-goodwill “revenue purchases” with real impairment risk, and insiders sold ~$33.8 million of stock into the 2025 spike and bought nothing — the founder/CEO/Chairman personally cashing ~$22 million. Governance is weak (three CEOs in two years, combined CEO/Chairman, options that vest on grant with no performance hurdles), the accounting history is troubled (a shut-down prior auditor, a 2024 restatement, still-open material weaknesses), and an active securities-fraud class action and four derivative suits hang over the promotional claims that drove the stock.

Every honest valuation of QUBT reduces to the same expression: net cash per share plus a low-probability option. DCF, EV/EBITDA and P/E are meaningless when revenue is under $1 million and earnings are interest income. On EV/Sales (~950×) QUBT sits at the richest extreme of an already-extreme cohort; on EV-to-cash it is the least stretched of the group because so much of its market cap is backed by the securities portfolio. The market is underwriting a ~$0.6 billion premium over cash for a quantum lottery ticket and a nascent foundry. This article takes no position; the analysis below argues the evidence.

2. Business Overview

What the company is. Quantum Computing, Inc. describes itself as an “integrated photonics and quantum optics” company aiming to deliver “accessible, affordable” quantum machines and photonic solutions. In practice it is an R&D organization with a small, recently-acquired photonics-components manufacturing arm, sitting on a very large securities portfolio. Corporate headquarters are in Hoboken, New Jersey; the R&D and prototyping foundry (“Fab 1,” also called the “AZ Chips Facility”) is leased space in the Arizona State University Research Park in Tempe.

Product lines (all pre-scale).

• Dirac series — Entropy Quantum Computing (EQC). QUBT’s flagship, a photonic optimization machine (marketed as Dirac-1/-3) built on a claimed “entropy computing” / energy-loss-feedback method operating at room temperature. It targets combinatorial-optimization problems. In Q1 2026 a Dirac-3 was placed on the “Quantum Corridor” network — described by management as the first data-center installation of the machine.
• Neurawave — photonic reservoir computing. A photonic reservoir-computing product aimed at time-series/AI inference workloads. The June 2026 order from Planck Dynamics (five NeuraWave units) is a representative deal size — small.
• Single-photon detection / imaging. LiDAR and remote-vibrometry systems using single-photon sensitivity.
• Quantum cybersecurity. A quantum random-number generator (uQRNG) and entanglement-based quantum-authentication prototypes intended to integrate into telecom fiber.
• TFLN photonic-chip foundry (Fab 1). A prototyping/small-batch fabrication facility for thin-film lithium niobate photonic integrated circuits. Management is explicit that Fab 1 is “an engine for innovation,” not a revenue engine; a much larger “Fab 2” is only in the planning phase.
• Acquired photonics components (from Feb–Mar 2026). Via LSI: Freedom Photonics (semiconductor lasers, ~25 issued/pending patents, some jointly owned with Northrop Grumman), EM4 (photonic/fiber-optic modules, a supplier to U.S. government and European defense/space programs), and OptoGration (chip manufacturing and device assembly/testing). Via NuCrypt: quantum-communication systems (entangled-photon generation/measurement) with customers including NASA and the U.S. Army Research Lab.

How it makes money — and how little. Historically, almost not at all. Revenue was $136K (2022), $358K (2023), $373K (2024), and $682K (2025) — the entire cumulative commercial output of the company over four years is under $1.6 million. Legacy revenue is a mix of small foundry deliveries and a NASA R&D subcontract. The Q1 2026 jump to $3.7 million is ~95% acquired (LSI + NuCrypt); organic revenue was ~$204K. The real income statement driver is interest income on the securities portfolio — $20.7M in FY2025 and $13.5M in Q1 2026 alone. Contract backlog was $16 million at 3/31/26, most of it acquired with LSI/NuCrypt.

Revenue is not recurring in any meaningful software sense. It is a blend of prototype hardware sales, government R&D subcontracts, and (now) photonic-component manufacturing to defense/telecom customers — lumpy, project-based, and low-margin. There is no disclosed anchor customer, no subscription base, and no unit-economics story.

Corporate lineage (relevant to the quality assessment). The listed entity traces back to Ticketcart, Inc. (2001) → Innovative Beverage Group Holdings (2009), was renamed Quantum Computing, Inc. in 2018, up-listed to Nasdaq in 2021, and became a quantum company through the June 2022 reverse merger with QPhoton (which brought in founder-technologist Dr. Yuping Huang). This shell-to-quantum lineage is directly relevant to the governance and accounting sections below.

Verdict: QUBT is a pre-commercial R&D company with a trivial, lumpy, low-margin revenue base and a very large securities portfolio. Its economic substance today is a bond fund with a photonics R&D appendage; the recent acquisitions add a small, low-margin manufacturing top line. This is not, on any current financial measure, an operating business of scale.

3. Industry Dynamics

The quantum-computing industry is pre-commercial and structurally unprofitable for equity holders. Across all listed pure-plays, aggregate revenue is a few hundred million dollars, not one earns an operating profit, and the cohort collectively burns more than $1 billion a year against tens of billions of market capitalization. The profit pool of the entire listed pure-play industry is negative. This is a field being funded, not by customers, but by capital markets and government.

The winning modality is genuinely unsettled, which is the crux of the risk. Competing physical approaches include superconducting qubits (IBM, Google, Amazon, Rigetti), trapped ions (IonQ, Quantinuum), quantum annealing (D-Wave), neutral atoms (Pasqal, QuEra, Atom Computing), silicon spin (Intel), topological (Microsoft), and photonics (PsiQuantum, Xanadu, and — at the fringe — QUBT). Credible fault-tolerance timelines span the late-2020s to the late-2030s. No investor, and arguably no physicist, can currently assign confident probabilities to which architecture reaches practical quantum advantage first. Equity prices across the group nonetheless embed the assumption of a specific winner.

The best-capitalized competitors are not the pure-plays. IBM, Google, Amazon, Microsoft, Intel and Nvidia pursue quantum with effectively unlimited balance sheets and can fund research from tens of billions of unrelated revenue. Against that, QUBT’s ~$50 million of annual R&D is a rounding error. In a technology race where progress correlates heavily with sustained R&D spend and world-class talent density, the small pure-plays are structurally disadvantaged on the one axis that matters — unless they own a genuinely differentiated, defensible approach. QUBT does not obviously do so (the Competitive Position section).

Government demand is real but is not a moat. The U.S. National Quantum Initiative, DARPA programs, national-lab procurement, sovereign quantum-key-distribution interest, and the June 2026 Trump executive orders bolstering U.S. quantum leadership create genuine, national-security-driven demand. But it is lumpy, low-margin, procurement-cycle-dependent grant and contract revenue, available to every credible player — a tailwind for the sector’s narrative and occasionally its revenue, not a source of durable pricing power or customer captivity for any one company.

Capital-cycle read (Marathon lens). This is a textbook late-stage capital cycle. Capital is flooding into a narrative; share counts and balance-sheet assets are exploding via serial equity issuance; returns on capital are deeply negative. IonQ’s share count is up ~87% in under four years; D-Wave went from ~266M to ~370M shares in a year; Rigetti roughly 2.5×'d its count; QUBT rebuilt ~$1.41B of cash from almost nothing by issuing into the spike. The asset-growth anomaly — the empirical tendency for the fastest asset-growers to deliver the worst forward returns — is flashing red across the whole cohort. Marathon’s framework would predict poor forward equity returns for the group as multiples mean-revert toward the (negative) fundamentals, with QUBT the most extreme constituent on the “assets grown via issuance” axis.

Verdict: structurally bad industry for equity returns at current valuations. The TAM is enormous and the national-security demand is authentic, but the profit pool is negative, the winning technology is unknown, the deepest pockets belong to hyperscalers, and the sector is priced as though the winner is already decided. Good science; bad place to underwrite equity value today.

4. Competitive Position

Name the moat: there isn’t one that surfaces in the financials. A moat must show up as a financial outcome — pricing power, customer captivity, scale economics, an intangible that competitors cannot replicate — that would deteriorate if the advantage disappeared. QUBT has $682K of revenue and negative operating margins; there is no financial outcome to attribute to a moat because there is essentially no business yet. Applying the Greenwald taxonomy honestly: there is no demonstrated cost advantage, no evidence of customer captivity/switching costs, no network effect, and no scale economics (QUBT is sub-scale versus every serious competitor). What remains is the claim of a proprietary intangible — the EQC method and TFLN photonic IP — which must be pressure-tested, not assumed.

The technology claim, assessed skeptically. QUBT’s differentiators are (i) “Entropy Quantum Computing,” a photonic, room-temperature approach it claims avoids the cryogenic complexity of superconducting and trapped-ion systems, and (ii) a thin-film lithium niobate photonic-chip foundry. The problems with treating this as a moat:

• No independent validation. There is no peer-reviewed quantum-advantage benchmark, no third-party replication, and no published head-to-head against superconducting/ion/annealing systems cited in the filings. In frontier quantum, extraordinary claims require independent benchmarking; QUBT’s are, on the public record, self-asserted.
• The gate-based machine is not built. On the Q1 2026 call the CEO stated that a key enabling metric — microring-resonator quality factor — sits at ~2 million versus a required ~10 million, that only “4.5 of 5” necessary conditions have been achieved, and that prototypes have not yet been started. Photonic gate-based competitors (e.g., PsiQuantum, Xanadu) are far better funded and are themselves years from fault tolerance; QUBT is, by its own account, behind them.
• The credible photonic names are not QUBT. Even within the photonic lane, the players taken seriously by the field are PsiQuantum (multi-billion-dollar funding) and Xanadu. QUBT is the smallest and least-validated listed pure-play, and its “entropy computing” branding is regarded by much of the field as outside the mainstream research program.
• IP is thin and partly inherited. QUBT cites a handful of its own U.S. patents plus ~23 issued / 16 pending from the 2022 QPhoton merger, and ~25 more from Freedom Photonics (some jointly owned with Northrop Grumman). This is a modest, partly-encumbered portfolio, not a fortress.

The one more-defensible asset is the fab, not the computer. A TFLN photonic-chip prototyping foundry is a physical, revenue-capable asset that could, in principle, become a real (if small) foundry-services business independent of whether the quantum computer ever works — analogous to selling picks and shovels. But at $120K of foundry revenue in Q1 2026 (management’s own figure), it is pre-commercial, it is leased rather than owned, and the far larger “Fab 2” needed for volume production does not yet exist. There is optionality here; there is not yet a moat.

Head-to-head. Versus IonQ (trapped ion, ~$130M revenue, deep enterprise/government relationships), D-Wave (annealing, a decade of commercial deployments and a real if small customer list), and Rigetti (superconducting, in-house fab, AWS/Azure availability), QUBT is behind on revenue, validation, partnerships, and cloud distribution. Its only comparative financial edge is that more of its market cap is backed by cash — a balance-sheet feature, not a competitive advantage.

Verdict: no durable competitive advantage. QUBT is a sub-scale participant in an unsettled race, with an unvalidated core technology, a thin IP base, and a nascent foundry that represents unproven optionality rather than a moat. If the “entropy computing” edge is real it has not been demonstrated where it counts; if it is not, there is no defensible franchise underneath the cash.

5. Growth History and Forward Opportunities

History: no organic revenue growth of consequence. Four years of commercial operation produced revenue of $136K → $358K → $373K → $682K. That is not a growth curve; it is noise near zero. Even the FY2024→FY2025 “83% growth” is $309K of absolute dollars. The only genuine revenue step is inorganic: Q1 2026’s $3.7 million, ~95% of which is the LSI and NuCrypt acquisitions closing mid-quarter. Organic (legacy quantum) Q1 2026 revenue was ~$204K — flat-to-nil versus history.

What growth QUBT does show is bought, not earned. The 2026 revenue ramp management will report is a function of consolidating LSI’s ~$20–25 million annual photonics-components run-rate (a conventional III-V/laser-module business acquired from a bankruptcy estate) and NuCrypt’s smaller contribution. This is real revenue, but it is (a) low- or negative-margin at current utilization (management guided gross margin toward “20–30%” only as volumes recover from a bankruptcy-depressed base), (b) not quantum revenue, and © purchased with ~$113 million of the cash hoard at ~83% goodwill. Buying a top line is not the same as building one.

Forward opportunities (all speculative, none quantified).

• Foundry services scale-up (Fab 2). The most tangible path — a real TFLN foundry could serve the broader photonics/AI-interconnect market. But Fab 2 is unfunded-by-plan, unsized, and years away; at $120K/quarter of current foundry revenue, the ramp is entirely prospective.
• Vertical integration. Management’s thesis is that owning lasers/detectors/packaging (LSI) plus quantum-comms (NuCrypt) lets QUBT sell complete “photonics-for-quantum” systems. Plausible as strategy; unproven in dollars, and it presumes the acquired teams stay and integrate.
• Government/defense. EM4’s existing U.S.-government and European defense/space relationships and NuCrypt’s NASA/Army ties are a credible channel, amplified by the June 2026 executive orders — but this is grant/procurement revenue, lumpy and low-margin.
• The quantum computer itself. The Dirac optimization machines and the (unbuilt) gate-based system are the blue-sky call option. Commercialization at scale is, on management’s own timeline and metric gaps, years out and probability-weighted low.

Verdict: low-quality growth. The organic growth history is effectively flat at near-zero; the forward “growth” that will appear in 2026 is acquired, low-margin, and non-quantum. There is real optionality in the foundry and in vertical integration, but nothing that has yet converted into durable, high-margin, organically-grown revenue. Growth here is a narrative and an acquisition line item, not a demonstrated capability.

6. Financial Quality

Revenue and margin. FY2025 revenue $682K; cost of revenue $615K; gross profit $67K (9.8% gross margin) — and Q1 2026 organic gross margin was negative (~−20%) on foundry/quantum deliveries, with the consolidated figure depressed by acquired-business underutilization. There is no operating leverage story because there is no revenue base to leverage.

Operating loss is large and widening; reported net loss is misleadingly small. FY2025 operating loss was −$51.1 million (vs. −$25.9M in 2024), reflecting a staffing and R&D ramp (headcount 75 → ~200 after acquisitions) and the Tempe foundry build-out. Yet FY2025 net loss was only −$18.7 million, because two non-operating items offset most of the burn: $20.7 million of interest income on the securities portfolio and a $11.75 million non-cash gain on the fair value of legacy QPhoton warrant derivatives. Q1 2026 shows the same optics: a net loss of just $4.1 million against an operating loss far larger, with $13.5 million of interest income doing the heavy lifting. The prior-year “profit” was worse: Q1 2025’s reported net income of $17 million was almost entirely a $23.6 million non-cash derivative revaluation gain — an accounting artifact, not earnings. Normalize out interest income and warrant marks, and the underlying business loses ~$50–60 million a year and the loss is accelerating.

Cash flow and burn. FY2025 operating cash burn was −$30.3 million (itself flattered by interest received), against −$16.2 million in 2024 — the burn is accelerating. Capex was only $6.7 million (the “foundry” is largely leased). Free cash flow was −$37 million. With ~200 staff and a run-rate operating loss now well above $60 million, gross cash burn is rising; the mitigant is that ~$54 million of annualized interest income offsets a large share of it, so net cash depletion is slow and the ~$1.41B hoard funds the operation for many years without a raise.

Balance sheet — the entire story. At 3/31/26: cash $257.7M + short-term investments $728.4M + long-term investments $422.8M = ~$1.41 billion of cash and securities, ~87% of $1.62B total assets. Crucially, the securities are 100% available-for-sale, investment-grade, short-dated debt — $564.8M U.S. Treasuries, $570.3M corporate bonds, plus small CDs/agency/ABS; nothing beyond five-year maturity; no equities, no crypto; gross unrealized loss just $3.0M. This is a genuine, liquid, near-cash portfolio — not a speculative or illiquid one. Against it sits only ~$3.7 million of capital-lease debt and no borrowings, no line of credit, and (following redemption of the legacy Series A preferred) no preferred overhang. PP&E net is just $16.9M; goodwill is $146.5M and intangibles $19.2M (both ~doubled/created by the Q1 2026 deals). Book value is ~$1.60B, or ~$7.1 per share; cash-and-securities per share is ~$6.2.

Dilution and SBC. Weighted-average shares went from ~29M (2021) to ~164M (2025 average) and 225.5M at 3/31/26 (~238M on the current data feed) — roughly a 4× increase in 18 months. Stock-based compensation was $8.7M in FY2025. The dilution, not leverage, is the shareholder cost of this model.

ROIC/ROE are not meaningful and should not be reported as if they were: with the equity base dominated by cash raised days ago and “earnings” that are interest income, conventional return-on-capital ratios describe a bond portfolio, not a business. The honest statement is that the operating return on capital is deeply negative and the reported return on equity is essentially the risk-free rate earned on the hoard.

Verdict: economics do not improve with scale because there is no scaled business — and the reported profitability is an artifact of the cash pile. The one unambiguous financial strength is balance-sheet quality: a large, liquid, unlevered, investment-grade securities portfolio that removes solvency risk for years. Everything below the interest-income line is a widening operating loss on negligible revenue.

7. Capital Allocation

The raise: genuinely shrewd, opportunistic corporate finance. This is the one place management earns real credit. During 2025 QUBT sold 86.25 million shares for $1,475.1 million across four private placements (not the ATM, which was dormant in 2025): Jan $100M @ $12.25, Jun $200M @ $14.25, Sep $500M @ ~$18.61, and Oct $750M @ ~$20.17. 81% of the total — $1.25 billion — was raised in September–October at ~$18–20, within days of the all-time high of $21.00 (Oct 7, 2025). Selling richly-valued story stock at the top of a mania to build a fortress balance sheet is exactly what a rational manager of an over-valued equity should do. Converting narrative into ~$1.5 billion of hard, liquid cash is the single most value-accretive act in this file.

The deployment: a bond fund, not a research program. The problem is what happened next. FY2025 investing activity deployed ~$822 million net into Treasuries and corporate bonds, versus ~$6.7 million of capex on actual lab/fab/hardware equipment. There is no evidence of a capital-deployment plan proportional to $1.5 billion of resources. The money sits earning the risk-free rate; the “return on capital” shareholders are getting on the hoard is a T-bill yield, and they are paying a ~$0.6 billion premium over that cash for the operating option. A company that genuinely believed it was on the cusp of a quantum breakthrough and had $1.4 billion in the bank would be spending aggressively on Fab 2, talent, and compute — not compounding at 4–5% in an AFS bond book.

The acquisitions: buying a revenue narrative at ~83% goodwill. QUBT spent a sliver of the hoard to bolt on a top line: LSI for $110 million cash (closed 2/2/26, out of Luminar Technologies’ bankruptcy estate; ~$90.9 million booked as goodwill, ~$12.7 million as intangibles — ~83% of the price above tangible net assets) and NuCrypt (~$2.5 million cash + 250K shares). Buying ~$20–25 million of low-margin, bankruptcy-depressed photonics-components revenue at ~83% goodwill is aggressive, and impairment risk is real if the “vertical-integration/technology-roadmap” synergies do not materialize. Strategically defensible as a way to acquire manufacturing capability and government relationships; financially, it is purchasing a revenue line rather than earning one.

Insider behavior: 100% sell, 0% buy — into the very strength they were selling stock into. Across the entire 2024–2026 Form 4 corpus (64 Form 4s, 12 Form 144s), there is not a single open-market purchase by any officer or director. Every insider cash transaction is a sale — ~2.50 million shares for ~$33.8 million gross, clustered at the 2025 peaks ($7.85–$19.92). The founder, Dr. Yuping Huang (Chief Quantum Officer → Interim CEO Apr’25 → CEO + Chairman Dec’25), personally sold 1.7 million shares for ~$21.96 million (including 1.0M at $14.42 in Sept’25) and gifted away 2.4 million more. Directors Turmelle (~$2.85M), Fagenson (~$1.56M), Shabani (~$1.04M) and others cashed out low-strike options into the spike. The only “buy-like” event was a director stock-grant retainer, not a purchase. Dollar amounts are modest against the company’s $1.5B raise, but the 100%-sell / 0%-buy skew, and the founder-CEO cashing ~$22M while running a $1.4B-cash balance sheet, is a textbook “insiders distributing into strength” signal — and it aligns perfectly with the corporate raise at the top.

Incentive alignment: poor. 2025 NEO equity awards were “exclusively stock options … fully vested upon approval” — immediate value transfer with no time or performance vesting and no revenue/ROIC/milestone hurdles. Directors received ~$605K each in options (versus ~$66–78K cash), then sold $1–3M of stock apiece. For 2026 the Compensation Committee is adding a “strategic scorecard” and multi-year vesting — an implicit admission that prior pay was structurally unaligned. No buybacks (rational — the stock trades above cash but the company is diluting, not repurchasing); a token, effectively-discontinued nominal dividend history.

Verdict: a split decision that nets negative on alignment. Management timed the equity issuance brilliantly — that is real and it protects shareholders from solvency risk. But the proceeds are undeployed, the acquisitions are goodwill-heavy revenue purchases, incentives are misaligned (fully-vested options, no metrics), and insiders sold ~$33.8 million with zero conviction buys while raising $1.25 billion from the public at the top. On the metric that most predicts future shareholder treatment — how management and insiders behave with the currency and the cash — the signal is that they view the stock as a funding vehicle, not an ownership stake to build.

8. Changes and Headwinds — Last Two Years

Strategic and structural changes.

• QPhoton legacy fully absorbed; pivot to “vertical integration.” The 2022 reverse merger that created the quantum company is now the base; the 2026 acquisitions (LSI, NuCrypt) mark a strategic shift from pure R&D toward owning photonics manufacturing and quantum-comms IP — an attempt to “manufacture a revenue line” and become a “photonics-for-quantum” supplier.
• The $1.5 billion balance-sheet transformation. The defining change: from a near-penny-stock micro-cap with ~$0 net cash to a ~$1.41 billion securities portfolio, executed via four 2025 PIPEs and ~4× dilution.
• Leadership churn. Three CEOs in two years — Robert Liscouski (terminated Jan 2024) → Dr. William McGann (resigned May 2025) → Dr. Yuping Huang (Interim Apr 2025, permanent Dec 2025, also Chairman). CFO turnover as well (Boehmler → Christopher Roberts, who is also General Counsel). This is instability at the top during the company’s most consequential period.
• Commercial “firsts.” Dirac-3 placement on the Quantum Corridor network (first data-center install), small NeuraWave orders (Planck Dynamics), and continued NASA/government subcontracts — genuine but immaterial in dollars.

Headwinds.

• Litigation overhang. A securities class action (D.N.J., filed 2/25/25, class period 3/30/20–1/15/25) alleges false/misleading statements about “customers, contracts and business operations,” specifically referencing QPhoton, NASA, “millionways,” “Quad M,” and the TFLN foundry — i.e., the very promotional claims that drove the stock. Four shareholder derivative suits (one alleging common-law fraud) target current and former officers/directors. All are stayed pending motions to dismiss. This is a material, unquantified overhang.
• Accounting and control history. The prior auditor was BF Borgers CPA PC — the firm the SEC charged and effectively shut down in 2024 for massive, systematic audit failures (“sham” audits) — since replaced by BPM LLP. QUBT restated FY2022–FY2023 in September 2024 (QPhoton purchase accounting, SBC, financing costs), and material weaknesses in internal control over financial reporting remained open at 12/31/2025 (control environment, risk assessment, IT general controls). For a company whose thesis depends on trusting management’s technical and commercial claims, the accounting track record is a red flag.
• Supply-chain concentration. Management flags that TFLN chip supply is “concentrated in China” — a geopolitical/sourcing risk for the one asset with genuine optionality.
• Sector-sentiment dependence. The stock’s fate is tethered to a volatile thematic basket; a single adverse headline (a skeptical remark from a credible figure, as in January 2025; a disappointing peer print; the Quantinuum IPO absorbing thematic capital) can crater it regardless of company-specific developments.

Verdict: the changes are financing- and acquisition-driven, and net-weaken the thesis on quality. The balance-sheet transformation removed solvency risk — a genuine positive. But leadership churn, a litigation cluster centered on the promotional claims, a troubled audit/restatement history with open control weaknesses, and dependence on a fickle sector narrative all cut against confidence in management and in the durability of the story.

9. Risk Analysis (Risk Matrix)

Reading the matrix. The dominant risks are valuation and technology, not solvency. The ~$1.41B of unlevered liquid cash makes a total loss unlikely and gives the equity a floor near ~$6–7. But the same cash is the reason the upside is capped by skepticism — you are paying a large premium over it for an option whose base rate of success is low. The risk profile is therefore asymmetric in an unusual way: bounded-ish downside to cash, but a wide, low-probability, headline-driven upside distribution — the classic lottery-ticket shape confirmed by the factor and drawdown data.

10. Valuation Discussion (Embedded Expectations)

Conventional multiples are meaningless and should be discarded. With FY2025 revenue of $682K, P/E is undefined (or reflects interest income), EV/EBITDA is negative, and DCF requires cash-flow forecasts the company cannot credibly furnish. On the two ratios that “work,” QUBT sits at opposite extremes: EV/Sales ~950× (P/S ~3,000×) — the richest in an already-absurd cohort — yet P/B ~1.2× and EV-to-cash the least stretched of the peer group, because so much of the market cap is backed by the securities portfolio.

Peer comparison — every listed pure-play trades on narrative and EV-to-cash, not fundamentals. The cohort shares one honest valuation frame: net cash per share plus a low-probability option. None earns an operating profit; all fund themselves by serial equity issuance into the mania.

*Last private-round implied mark. Sources: prior peer research (see Source Appendix); public financial data confirmed QUBT FY25 revenue $682K.

The structural nuance is decisive. QUBT’s cash (~$1.41B) is ~68% of its market cap, so its absolute EV (~$0.6B) is the smallest in the cohort despite a ~$2B market cap — more of the cap is “backed” by real securities than at any peer. Yet on EV/Sales (~950×) it is the richest because its revenue is nearest to zero. Both statements are true simultaneously, and they define the security: relative to the group, QUBT is the purest “cash-shell-plus-a-lottery-ticket.” The capital-cycle read reinforces caution — the whole cohort is funding explosive asset/share growth with issuance (IONQ shares +87% in <4yr; QBTS 266M→370M in a year; RGTI ~2.5× its count; QUBT ~4× in 18 months), the exact configuration the asset-growth anomaly associates with poor forward returns.

The only honest frame is sum-of-the-parts: cash + option. Decompose the ~$8.66 share price:

• Net cash and securities: ~$6.2/share (~$1.41B / ~226M shares), or ~$6.0 on the ~238M data-feed count. This is liquid, investment-grade, and real — a hard-ish floor absent value-destructive deployment or a litigation shock.
• Book value: ~$7.1/share (adds PP&E, goodwill, intangibles, working capital to cash).
• The operating premium: ~$1.7–2.4/share (~$0.4–0.6B of EV) — what the market pays above cash for the quantum computer, the foundry optionality, LSI/NuCrypt, and the ~$54M/yr interest stream. On ~$25M of (acquired, low-margin) forward revenue that is ~20–24× sales for the operating business; on organic quantum revenue it is effectively infinite.

Embedded-expectations analysis — what must be true to justify ~$8.66? The market is underwriting roughly $0.5 billion of value creation from the operating business above its cash. To make that price fair on fundamentals, an investor must believe some combination of: (i) the foundry (Fab 1→Fab 2) scales into a real, high-margin photonics business worth several hundred million; (ii) LSI/NuCrypt integrate into a growing, profitable photonics-for-quantum franchise rather than impairing; and/or (iii) the EQC/gate-based quantum program produces a genuinely differentiated, commercially-valuable machine. Each is possible; none is demonstrated; and the base rates (a sub-scale, unvalidated player against hyperscalers and better-funded pure-plays) argue against paying up. The market is correctly pricing the cash and the interest income; it is arguably mispricing — over-paying for — the operating option, given the evidence gaps, governance discount, and litigation.

Scenario sketch (illustrative, not a target).

• Bear: the narrative fades, sentiment normalizes, and the stock converges toward cash/book as dilution and burn grind on and/or an impairment or litigation shock lands — value gravitates to the ~$6–7 cash/book zone (potentially lower if the cash is deployed poorly or the option is written to zero).
• Base: the stock oscillates as a cash-plus-option instrument, range-bound between its cash floor and a narrative premium, with the premium expanding and contracting on sector headlines — roughly the recent $6.5–$11.5 band.
• Bull: a genuine catalyst (independently benchmarked quantum-advantage result, a real foundry revenue ramp, or a sustained sector melt-up) re-rates the operating premium sharply higher; given the lottery-shaped factor profile and low borrow, squeezes toward and beyond prior highs are possible without any fundamental change.

No price target, no recommendation — this section describes embedded expectations and scenarios only. The judgment call lives solely in the opinion block above.

11. Variant Perception

Consensus belief. Among the retail/momentum base that sets QUBT’s marginal price, the consensus is bullish-thematic: “quantum is the next AI, QUBT is a cheap, low-priced pure-play with a fortress balance sheet and a real chip fab, and Washington is now behind the sector.” Among fundamental investors, the near-consensus is the mirror image: “a promotional, unprofitable story stock trading at an absurd EV/Sales, priced far above the cash inside it.”

Strongest bull case. QUBT is a ~$1.4B liquid-cash box with essentially no debt, funded for a decade of R&D from interest income alone, run by a founder-physicist who has already proven he can convert narrative into hard cash at the top of a cycle. You are buying an option on a differentiated, room-temperature photonic approach and a real TFLN foundry and a newly vertically-integrated photonics-components business with government/defense channels — with a cash floor limiting downside and a lottery-shaped, headline-driven upside. In a sector melt-up, the low absolute price and low borrow make it a high-torque instrument.

Strongest bear case. It is a bond fund in a costume. The operating business earns $682K, loses $50M+, has no validated technology and no moat, is run by management that sold ~$34M of personal stock (zero buys) while raising $1.25B from the public at the top, carries a shut-down-auditor/restatement/open-material-weakness accounting history and an active fraud class action, and is priced at ~$0.6B of EV over its cash for all of it. The asset-growth anomaly and the capital cycle both predict poor forward returns for the cohort; QUBT is the most extreme constituent. The cash floor caps the loss but also caps the rational upside, because everything above cash is narrative.

The 3–5 assumptions that actually matter.

1. Does the EQC/gate quantum program ever produce independently-validated advantage? (Bull needs eventually yes; bear needs no/decades. Current evidence: unbuilt, unvalidated.)
2. Does the foundry become a real, high-margin business? (The most tangible swing factor; currently $120K/quarter.)
3. Will management deploy the $1.4B into value creation, or keep it in T-bills / spend it on goodwill-heavy deals? (Deployment quality is the key capital-allocation fork.)
4. Does sentiment/regime stay favorable to the quantum basket? (Sets the near-term price far more than fundamentals.)
5. Does the litigation or an impairment crystallize into a balance-sheet hit? (The main threat to the cash floor.)

What would falsify each side. Bull is falsified by: a failed/again-delayed gate prototype, flat foundry revenue through 2026, another dilutive raise despite the hoard, an LSI impairment, resumed insider selling, or an adverse litigation ruling. Bear is falsified by: a peer-reviewed or third-party-benchmarked quantum-advantage result, a genuine multi-quarter foundry/photonics revenue ramp with improving margins, insider open-market buying, and disciplined cash deployment into the business.

Factor-positioning read (from the tape). QUBT loads most heavily on a “Space & Quantum Innovators” custom factor (beta ~4.2) and on Market/Growth, with negligible Value or Quality — a high-beta (~2.5), momentum/lottery profile (three-year annualized ~+90% but max drawdown −95.6%; one-year −55%). The marginal price-setter is flow and narrative, not DCF. This is precisely the configuration in which consensus can be offsides in either direction: crowded-bullish retail momentum can overshoot the cash-plus-option fair value on the way up, and abandonment can overshoot it on the way down. The variant-perception opportunity, if there is one, is not “quantum will/won’t work” — it is recognizing that the stock is a cash box with a lottery ticket stapled on, and pricing each piece honestly rather than paying the narrative premium.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the exact NuCrypt purchase price and goodwill allocation? Not separately quantified in the FY2025 10-K (post-period); confirm from the Q1’26 10-Q business-combination note.
2. Were the Sep/Oct 2025 PIPE purchasers institutional, or did any insiders/related parties participate? Resale S-3s were filed; identity of the buyers affects the “distribution into strength” read.
3. What is the true consolidated cash-burn run-rate post-acquisitions? Management declined to give a normalized quarterly OpEx figure on the Q1’26 call; the $19.8M included ~$6M one-time M&A costs. How much does interest income actually offset going forward as headcount (~200) and Fab 2 planning ramp?
4. What is the real, arms-length foundry revenue trajectory? Q1’26 foundry revenue was ~$120K; is there a credible path to material foundry-services revenue, or does that require Fab 2 (unfunded-by-plan)?
5. What are the gating technical milestones and dates for the gate-based machine? The Q-factor gap (2M → 10M) and “4.5 of 5 conditions” need concrete timelines; peers target ~2029.
6. Will management articulate a capital-deployment plan proportional to $1.4B, or continue to hold T-bills and make small goodwill-heavy acquisitions?
7. How large is the litigation exposure, and what is the timeline/probability distribution on the class action and derivative suits?

14. What Must Be True

Bull case — for the operating premium over cash to be justified and expand, ALL of the following must broadly hold:

• The foundry (Fab 1 → Fab 2) scales into a real, higher-margin photonics-services business — revenue moving from ~$120K/quarter toward tens of millions with improving gross margin.
• LSI/NuCrypt integrate successfully: the acquired teams stay, margins recover from bankruptcy-depressed levels toward 20–30%+, and the “photonics-for-quantum” cross-sell produces organic growth rather than a goodwill impairment.
• The EQC/gate-based quantum program produces at least one independently-benchmarked result that the field takes seriously — converting “marketing” into “validated.”
• Management deploys the cash into value creation and stops distributing (insiders stop selling; no dilutive raises with $1.4B in the bank).

Bull falsification test: if, by year-end 2026, foundry revenue is still sub-$1M/quarter, the gate machine remains unprototyped, an LSI impairment is taken, or insiders resume net selling — the operating premium is unsupported and the stock should converge toward cash/book (~$6–7).

Bear case — for the stock to de-rate toward (or below) cash, the following must hold:

• The quantum technology continues to lack independent validation and slips further behind better-funded competitors.
• Organic revenue stays negligible and the acquired revenue proves low-margin and/or impairs.
• Sector sentiment normalizes and the thematic bid fades (or a single adverse headline shocks the basket).
• The litigation and/or accounting overhang produces a tangible cost or a further loss of confidence.

Bear falsification test: if QUBT delivers a peer-reviewed / third-party-benchmarked quantum-advantage result and a sustained multi-quarter foundry/photonics revenue ramp with improving margins and insider open-market buying — the “bond fund in a costume” thesis is broken and the operating business would deserve a real, growing valuation independent of the cash.

The pivot both cases share: value above the ~$6–7 cash/book floor is entirely a function of whether the operating business becomes real. Today it is not, and insiders and management have voted with their own shares and their own capital raises on how they see it.

The Source Appendix (see Source Appendix) follows as Appendix B in the combined report.

APPENDIX A — Standard Diligence Questionnaire

Quantum Computing, Inc. (NASDAQ: QUBT) · Report date 2026-07-11

Answers are grounded in primary filings and public data, labeled Fact / Interpretation / Assumption where it matters. Where a question does not map to QUBT’s business model, the correct analog is given.

General

What thoughtful questions have other investors asked about this company? The recurring, sharp questions from the sell-side/investor base (per the Q1’26 call and filings) are: (1) What is the normalized post-acquisition OpEx run-rate? — management declined to answer. (2) How fast does foundry revenue ramp, and how does it compare to the ~$20–25M LSI run-rate? — answered vaguely; foundry is “orders of magnitude below” LSI. (3) Where are the gate-based machine and next Dirac in development? — still at the engineering-hurdle stage (Q-factor 2M vs 10M needed; prototypes not started). (4) What is the deployment plan for $1.4B? — no concrete answer; “Fab 2” only in planning. The unasked-but-central question is the one this article foregrounds: why is the stock worth ~$0.6B more than the cash inside it?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Fact/Interpretation. “Earnings” is a misnomer — reported net loss (−$18.7M FY25) is dominated by non-operating interest income ($20.7M) and a warrant-derivative mark ($11.75M). The underlying operating loss (−$51.1M) is widening, not cyclical. Interest income is at a cyclical high (large cash pile × ~4–5% rates); if rates fall, the interest offset shrinks and the reported loss worsens.

Driven by external environment or internal actions? Both — the reported loss is a function of the (internally-chosen) securities portfolio size and (external) interest rates; the stock price is driven overwhelmingly by external sector sentiment.

How stable are revenues? Fact. Extremely unstable and near-zero: $136K→$358K→$373K→$682K (FY22–25), now step-changed by acquisitions. Lumpy, project/grant-based, no recurring base.

Outlook for products/services? Interpretation. Quantum computer: years out, unvalidated. Foundry: prospective, pre-commercial. Acquired photonics components (LSI/NuCrypt): a real but low-margin, government/telecom-facing business recovering from a bankruptcy-depressed base.

How big will this market be? Interpretation. Quantum computing TAM is large and growing (tens of billions over the next decade on optimistic forecasts), international, and government-anchored — but the profit pool for pure-play equity is currently negative, and QUBT’s share of any realized market is speculative.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More — new entrants, the pending Quantinuum IPO, and hyperscaler programs (IBM/Google/Amazon/Microsoft/Nvidia) intensify competition; QUBT is sub-scale on R&D.

How profitable is the business (ROIC, ROE)? Fact. Operating ROIC is deeply negative; reported ROE approximates the risk-free rate earned on the cash hoard, which is not a business return. Conventional return metrics are not meaningful (the Financial Quality section).

How profitable is the industry — competitors, barriers? Fact. No listed pure-play earns an operating profit; the industry’s profit pool is negative. Barriers to entry are high on technology/talent but low on capital right now (markets fund anyone with a quantum story) — a dangerous combination (Marathon capital-cycle red flag).

Can the business be easily understood? The balance sheet (a bond fund) is simple; the technology (entropy/photonic quantum computing) is highly specialized and, critically, unvalidated by third parties.

Undermined by foreign low-cost labor? Not directly labor; but the key TFLN chip input supply is flagged as concentrated in China — a sourcing/geopolitical risk.

Do brands matter? Nature of competition? Switching costs? No consumer brand. Competition is technological (which modality wins) and reputational (which team the government/enterprises trust). There are no demonstrated customer switching costs — there is barely a customer base.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Minimal. If anything, the intangibles/goodwill ($166M combined) are richly carried (~83% of the LSI price) and are an impairment risk, not a hidden asset. Any technology value is expensed R&D, not capitalized.

Off-balance-sheet liabilities? None material disclosed beyond ordinary operating leases; no debt, no convertibles, no pension. The unquantified contingent liability is the securities-fraud class action and four derivative suits.

How conservative is the accounting? Interpretation — a concern. Prior auditor (BF Borgers) was SEC-shut-down; FY22–23 were restated in Sept 2024; material weaknesses in ICFR remained open at 12/31/25; recurring warrant-derivative marks distort EPS in both directions. Treat management’s non-audited claims skeptically.

How CapEx-hungry is the business? Currently low ($6.7M FY25 capex; the “foundry” is leased). But the stated ambition (Fab 2, “where quantum manufacturing becomes scalable”) implies a large future capital requirement that is unfunded-by-plan and unsized.

Capital Allocation & Management

How much FCF does the business generate, and how is it used? Fact. FCF is negative (−$37M FY25). “Cash generation” is external (equity issuance) and interest income, not operations. The philosophy, revealed by action: raise story stock at the top, park it in Treasuries, make small goodwill-heavy acquisitions.

Significant acquisitions recently? Fact. Yes — LSI ($110M cash, Feb 2026, ~83% goodwill) and NuCrypt (~$2.5M cash + 250K shares, Mar 2026); plus the foundational 2022 QPhoton reverse merger.

Buying back shares? No. Issuing shares to insiders? Yes — options that vest fully on grant, plus ~4× total dilution via PIPEs (mostly external).

Compensation policy / motivations of management? Fact/Interpretation. Modest cash salaries (CEO ~$508K 2025), but option-loaded, immediate-vest, no performance hurdles historically (a “strategic scorecard” is only being added for 2026). Directors received ~$605K each in options, then sold $1–3M of stock. Combined with 100% insider selling and zero buys, incentives read as extraction/monetization rather than long-term ownership alignment.

Valuation & Market Data

ADR / MLP / K-1? No — a U.S. C-corp common stock on Nasdaq; standard 1099 treatment.

Dividend policy? Effectively none (token, discontinued nominal history). All returns are price-driven.

How profitable is the business? Not — see above.

Is net income diverging from cash from operations? Fact. Yes, materially. FY25 net loss −$18.7M vs. operating cash flow −$30.3M; both are distorted by interest income and non-cash warrant marks. Neither figure reflects the true ~$50–60M operating burn.

Risks & Downside

What factors would cause the stock to decline? Sector-sentiment normalization; a skeptical high-profile comment (as in Jan 2025); disappointing peer prints or the Quantinuum IPO absorbing thematic capital; another dilutive raise; an LSI impairment; an adverse litigation development; resumed insider selling; a failed/delayed gate-machine milestone.

Risk of a catastrophic loss? Interpretation — low, but non-zero. The ~$1.41B of liquid, unlevered, investment-grade cash makes a total loss unlikely absent fraud, a catastrophic litigation outcome, or reckless capital deployment. The realistic bear outcome is not zero — it is convergence toward cash/book (~$6–7), i.e., a large loss from ~$8.66 but not a wipeout.

Chance of a total loss? Low. The cash floor is the single best feature of the security.

Recent News & Events

Has the business environment changed recently? Fact. Yes — favorably at the sector/narrative level (June 2026 Trump quantum executive orders; continued government emphasis) and structurally at the company level (LSI/NuCrypt acquisitions closed Q1’26, transforming the revenue line and headcount 75→~200). The Quantinuum IPO (June 2026) adds a large, richly-valued quantum “currency” to the group.

Significant acquisitions? LSI and NuCrypt (see above).

Change in accounting policies? Auditor changed (BF Borgers → BPM LLP); FY22–23 restated (Sept 2024); purchase accounting for LSI/NuCrypt is preliminary.

Recent changes — new markets, facilities, management? New markets/channels via LSI (defense/space/telecom) and NuCrypt (quantum comms, international); Fab 1 ramping small-batch, Fab 2 in planning; management: Dr. Yuping Huang became permanent CEO (Dec 2025) and Chairman — the third CEO in two years.

APPENDIX B — Source Appendix

Quantum Computing, Inc. (NASDAQ: QUBT) · Report date 2026-07-11

Primary sources first. All SEC filings are for CIK 0001758009, available on SEC EDGAR. Figures reconciled to filings; public third-party data used for cross-checks and labeled as such.

Primary — SEC filings (EDGAR, CIK 0001758009)

Primary — Company communications

Secondary — Quantitative aggregators (cross-checks; reconcile to filings)

Secondary — Peer / industry cross-read (public filings)

External reference (public)

Note on labeling: Facts are tied to primary filings/transcripts wherever possible. Interpretations (moat assessment, “bond fund in a costume” framing, valuation judgment) are the analyst’s, labeled as such in this article. Public third-party aggregator figures are signals cross-checked against the filings; where a discrepancy exists, the filing governs.